Effects of apatinib combined with chemotherapy on tumor markers, angiogenesis and bone marrow suppression in patients with stage Ⅲ B-Ⅳ colorectal cancer / 肿瘤研究与临床

ABSTRACT

Objective:To explore the effects of apatinib combined with chemotherapy on tumor markers, angiogenesis and bone marrow suppression in patients with stage Ⅲ B-Ⅳ colorectal cancer. Methods:A total of 60 patients with stage Ⅲ B-Ⅳ colorectal cancer who were treated in Yizheng People's Hospital of Jiangsu Province from March 2018 to May 2019 were selected, they were divided into the observation group (30 cases) and control group (30 cases) according to the random number table method. The control group was treated with conventional intravenous chemotherapy, while the observation group was treated with apatinib on the basis treatment of the control group. The remission rate and incidence of bone marrow suppression were compared between the two groups, and the expressions of carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), carbohydrate antigen 242 (CA242), vascular endothelial growth factor (VEGF) and microvessel density (MVD) before and after treatment were also compared. Results:The remission rate in the observation group was higher than that in the control group [86.7% (26/30) vs. 63.3% (19/30)], and the difference was statistically significant ( χ2 = 4.356, P = 0.037). After treatment, the levels of CEA, CA199 and CA242 in the observation group [(3.1±0.8) ng/ml, (112±17) U/ml and (27±6) U/ml] were significantly lower than those in the control group [(6.6±1.1) ng/ml, (169±22) U/ml and (39±7) U/ml], and the differences were statistically significant (t values were -14.209, -11.102 and -7.384, all P < 0.01). After treatment, the levels of VEGF and MVD in the observation group [(41±5) ng/ml and 18±3] were significantly lower than those in the control group [(80±7) ng/ml and 33±5], and the differences were statistically significant (t values were -23.161 and -13.529, both P < 0.01). The incidence of bone marrow suppression was 10.0% (3/30) in the observation group and 6.7% (2/30) in the control group, and there was no statistical difference between the two groups ( P = 1.000). Conclusion:Apatinib combined with chemotherapy for treatment of patients with stage Ⅲ B-Ⅳ colorectal cancer can further improve the short-term efficacy, reduce the level of tumor markers, inhibit angiogenesis, and do not increase the incidence of bone marrow suppression.